| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514625000 |
R is acyclic
| 272 |
| 514617000 |
R contains benzene ring
| 254 |
| 514616000 |
Plural carboxamide groups or plural C=O groups bonded directly to the same nitrogen
| 118 |
| 514614000 |
N-N containing (e.g., aminimine, hydrazine, etc.)
| 25 |
| 514624000 |
Three-membered ring in R | 3 |
| 20100048721 | USE OF 2,2,3,3, TETRAMETHYLCYCLOPROPANE CARBOXYLIC ACID DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS - The invention relates to the use of 2,2,3,3 tetramethylcyclopropane carboxylic acid derivative compounds for the preparation of a medicament for treating a psychiatric disorder preferably a bipolar disorder. The invention additionally relates to the use of the compounds for the preparation of an inhibitor of MIP synthase and to a pharmaceutical composition comprising the compounds for treating a psychiatric disorder. A method for treating a psychiatric disorder preferably a bipolar disorder and a method for inhibiting an enzyme having MIP synthase activity is provided. | 02-25-2010 |
| 20100160443 | COMPOUNDS USEFUL FOR TREATING NEUROLOGICAL DISORDERS - The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration is also provided. | 06-24-2010 |
| 20140357722 | Use of Malononitrilamides in Neuropathic Pain - Provided herein are compounds and pharmaceutical compositions for use in the treatment of neuropathic pain and the neuropathic pain syndromes. | 12-04-2014 |
| 514623000 |
Plural alicyclic rings in R | 2 |
| 20110160309 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS - Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the preparation of compounds and pharmaceutical compositions thereof useful in the treatment of, for example, inflammation, cancer, multiple myeloma, cachexia, cardiovascular disease, anti-infectious, diabetes, otitis media, sinusitis and transplant rejection. | 06-30-2011 |
| 20120238634 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS - Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the preparation of compounds and pharmaceutical compositions thereof useful in the treatment of, for example, inflammation, cancer, multiple myeloma, cachexia, cardiovascular disease, anti-infectious, diabetes, otitis media, sinusitis and transplant rejection. | 09-20-2012 |
| Entries |
| Document | Title | Date |
|---|
| 20080214673 | Acetylene Derivatives - The invention provides compounds of formula (I) | 09-04-2008 |
| 20080269341 | Method for Correcting a Lipid Imbalance in a Subject - The present invention relates to methods for the treatment of a disease or condition associated with lipid imbalance, comprising (a) decreasing arachidonic acid (AA) levels, (b) increasing docosahexaenoic acid (DHA) levels, (c) increasing DHA/AA ratio or (d) any combination of (a)-(c) in a subject using fenretinide. The invention also relates to diagnostic and screening methods based on the determination of lipid levels. | 10-30-2008 |
| 20090088478 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS - The present invention relates to compounds as inhibitors of enzymes having histone deacetylase activity, to the processes for the preparation of those compounds, and to their use for the treatment of diseases which are associated with hypoacetylation of histones and/or other molecules, or in which induction of hyperacetylation has a beneficial effect for example by inhibition of proliferation and/or induction of differentiation and/or induction of apoptosis in transformed cells, such as cancer. Furthermore, the compounds are useful for the treatment of other proliferative diseases, for therapy or prophylaxis of conditions associated with abnormal gene expression. | 04-02-2009 |
| 20090170952 | COLCHICINE COMPOSITIONS AND METHODS - Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | 07-02-2009 |
| 20100048714 | Methods and Compositions Related to Inhibition of Ceramide Synthesis - Disclosed are compositions and methods related to the ceramide synthesis pathway and various diseases and disorders associated therewith, such as insulin resistance and inflammation. | 02-25-2010 |
| 20100160441 | NOVEL COMPOUNDS - The invention is concerned with compounds of formula I: | 06-24-2010 |
| 20100267833 | Compositions and methods for preventing or treating an inflammatory response - The present invention relates to methods for modulating the inflammatory response of respiratory tract cells using an agent that increases ceramide levels in the cells of the respiratory tract. | 10-21-2010 |
| 20100298443 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS WITH RETINYL DERIVATIVES - Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies. | 11-25-2010 |
| 20100331417 | TREATMENT OF NEURAL DISEASES OR CONDITIONS - Compounds, methods, uses, compositions, kits and packages for the prevention and/or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and/or analogs, derivatives, pro-drugs, precursors thereof, and/or salts thereof, are described. | 12-30-2010 |
| 20110028561 | PROTECTION OF NEURAL RETINA BY REDUCTION OF ROD METABOLISM - Described herein are methods for treatment or prevention of retinal dysfuntion by reduction of rod cell energy demand. Particular embodiments include methods for improving rod-mediated retinal function in a developing retina by administering an agent that reduces energy demand in the rod cell. Such agents that target rod cell energy demand can be administered to a subject at risk for retinal dysfunction to modify rod-cell function, such that the retina reaches retinal maturity. Also described herein are methods for suppressing the visual cycle in a developing rod cell by contacting the cell with an agent that reduces the energy demand of the rod cell. | 02-03-2011 |
| 20110294891 | METHODS AND COMPOSITIONS FOR TREATING OPTHALMIC CONDITIONS WITH RETINOL DERIVATIVES - Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies. | 12-01-2011 |
| 20120108665 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS - We describe methods and compositions for treating ophthalmic conditions associated with angiogenesis, vascular leakage, and/or damage to ganglia. | 05-03-2012 |
| 20120238632 | MODULATORS OF RETINOL-RETINOL BINDING PROTEIN (RBP)-TRANSTHYRETIN (TTR) COMPLEX FORMATION - Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies. | 09-20-2012 |
| 20120283331 | Anti-Inflammatory Quinic Acid Derivatives for Radioprotection/Radiomitigation - Disclosed are methods of use of analogs of quinic acids or shikimic acids for protection from the harmful effects of radiation when administered either prior to radiation exposure, after radiation exposure, or both. These methods are useful for treating humans and animals exposed to radiation and at risk for radiation sickness and/or death as the result of radiation exposure. | 11-08-2012 |
| 20120309835 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES - Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject. | 12-06-2012 |
| 20120316243 | ENHANCED BIMATOPROST OPHTHALMIC SOLUTION - A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein. | 12-13-2012 |
| 20130012591 | PROPHYLAXIS OF SKIN CANCER WITH RETINAMIDES - Provided in certain embodiments herein are methods of prophylaxis of skin cancer in individuals having a heightened risk of skin cancer with a fenretinide agent. | 01-10-2013 |
| 20140113973 | TREATMENT OF NEURAL DISEASES OR CONDITIONS - Compounds, methods, uses, compositions, kits and packages for the prevention and/or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and/or analogs, derivatives, prodrugs, precursors thereof, and/or salts thereof, are described. | 04-24-2014 |
| 20140155487 | METHOD FOR CORRECTING A LIPID IMBALANCE IN A SUBJECT - The present invention relates to methods for the treatment of a disease or condition associated with lipid imbalance using fenretinide. The invention also relates to diagnostic and screening methods based on the determination of lipid levels. | 06-05-2014 |
| 20140243414 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS - The invention provides pharmaceutical compositions comprising a cholesteryl ester transfer protein (CETP) inhibitor and a water-insoluble concentration-enhancing additive, which exhibit improved bioavailability. The invention also provides methods of treating cardiovascular disorders comprising the administration of the pharmaceutical compositions comprising a CETP inhibitor. | 08-28-2014 |
| 20150111969 | J-SERIES PROSTAGLANDIN-ETHANOLAMIDES AS NOVEL THERAPEUTICS - Provided is a compound of formula (I): | 04-23-2015 |
